Getting focused has been the catchphrase of the pharma industry for a couple of years, and its reach includes contract manufacturers no less than the Big Pharma players. French CMO Novasep said today that its "back to basics" strategy, which included some changes in its manufacturing network, has paid off with improved financials.
French contract manufacturer Novasep says that its expansion of its highly potent active pharmaceutical ingredients manufacturing operations at its plant in Le Mans, France, is complete, signed off on by the FDA and now being scaled up for commercial use.
Targeted drugs are becoming the focus of a growing number of companies, and manufacturers are responding by building more antibody drug conjugate manufacturing capacity.
Novasep is continuing to expand its contract manufacturing capabilities, now spending $38.8 million to build a commercial API plant in Mourenx, France.
French contract pharmaceutical manufacturer and supplier Novasep is again expanding its production capacity, the third, and largest, project it has started or completed this year.
CMO Novasep is investing €3 million ($3.7 million) to expand its highly potent active pharmaceutical ingredient production, pouring the cash into its Le Mans, France, facility.
The French company will use the money for "growth projects," including new technologies for purifying biopharmaceutical and pharmaceutical APIs.
Contract manufacturers in the West are rising to the challenge of their competitors in the East by providing value in the form of ingenuity rather than cost savings. And the tactic appears to be
Novasep has become the third contract manufacturer in less than two months to announce potent compound safety certification. The certification, granted by SafeBridge, applies to portions of its Le